Verified employee & interview reviews

Neuberg Diagnostics Reviews

Chennai, Tamil Nadu

5.0/ 5

1 review

Neuberg Diagnostics Private Limited is a prominent multinational healthcare organization and stands as one of India's leading diagnostic laboratory chains. Headquartered in Chennai, Tamil Nadu, the company was officially incorporated in January 2017 and operates as a unified alliance of landmark diagnostic institutions. The alliance, which formally came together under the Neuberg banner in 2018, integrates several prominent generation path-labs with over two centuries of combined institutional experience, including Anand Diagnostic Laboratory in Karnataka, Supratech in Gujarat, Ehrlich in Tamil Nadu, Global in South Africa, and Minerva in Dubai. The core operations of Neuberg Diagnostics are focused on providing a comprehensive range of clinical laboratory testing services, encompassing advanced pathology, radiology, genomics, and preventive health checkups. In its pathology vertical, which contributes approximately 91.2% to its fiscal year 2025 revenue, the company performs over 5,000 pathological investigations and specialized test menus. This includes high-margin specialty and genomic portfolios, managed via dedicated arms like the Neuberg Center for Genomic Medicine, which offers cutting-edge cytogenetic and molecular diagnostic services utilizing data science and Artificial Intelligence tools. The radiology segment accounts for around 8.8% of its revenue, providing diagnostic imaging services like digital X-rays, ECGs, mammography, and sonography. Neuberg Diagnostics operates a deeply diversified business profile with a robust operational footprint. As of late 2025, the company manages an extensive network of 179 laboratories and more than 1,500 touch points across over 70 cities in 18 Indian states, with its strongest market presence concentrated in the western and southern regions. Internationally, the alliance has successfully expanded its healthcare footprint to the United Arab Emirates, South Africa, and Sri Lanka. The business model effectively balances both business-to-consumer (B2C) and business-to-business (B2B) channels, with B2C accounting for roughly 55% of revenue in the first half of fiscal year 2026. Historically, the company’s growth strategy has been heavily driven by strategic mergers and acquisitions to strengthen its geographical diversification. Notable acquisitions include Pulse Diagnostics, AG Diagnostics, Avishkar Labs, Sehgal Path Labs, Magnum Labs, and more recently, Vijaya Medical Center, Paniv Healthcare, and Gemini Scans. To fuel its continuous acquisition pipeline, Neuberg successfully raised INR 900 crore through optionally convertible debentures in January 2025. Financially, Neuberg Diagnostics reported a consolidated operational revenue of INR 853 crore for the fiscal year ending March 31, 2025, representing a steady annual growth rate of 13%. Led by Founder, Chairman, and Managing Director Dr. G.S.K. Velu, the company is actively preparing for an initial public offering (IPO) targeted for 2026, aiming to further expand its cutting-edge, affordable diagnostic solutions globally.